Prof. James Hansen (left) and Prof. Jiangbing Zhou (right).
Interview with Dr. Jianbing Zhou
- Could tell us about yourself, your background, and how you got to work on NF?
- Can you explain, in simple terms, how Nanoparticles and antibodies are being used in your pre-clinical research project for gene delivery and immunotherapy in NF2?
- How do you envision this research advancing the current treatment options for individuals with NF2? What potential benefits might it offer to the NF2 community?
The gene replacement approach, whether delivered through nanoparticles or antibodies, has a major advantage over current NF2 treatments as it directly addresses the genetic cause of the disease. The antibody-based therapy may also eliminate distal tumor cells by triggering an immune response. If successful, our approach could offer a novel and effective management strategy for the NF2 community.
- Are there any specific challenges or risks associated with using antibodies for gene delivery and immunotherapy that the NF2 community should be aware of?
At present, we are not aware of any major challenges or risks associated with using antibodies for gene delivery and immunotherapy. However, we remain vigilant and will closely monitor these aspects in our future studies to ensure the safety and efficacy of our approach.
- What stage is your research currently at, and what are the next steps in terms of bringing this approach closer to clinical trials or potential implementation for NF2 patients?
We are currently in the process of rigorously characterizing the specific antibody for NF2 treatment, using relevant disease models. If our findings prove promising, our next step will involve collaborating with industrial partners to humanize the antibody and prepare for clinical trials.
- How can individuals within the NF2 community stay informed about the progress of your research and any future developments related to this project? Is there a way for them to participate or contribute in any manner?
Rest assured that we will keep the NF2 community informed about any significant progress we make. Stay tuned for updates! As we move forward, we may require assistance from the community, especially in the realm of clinical translation, following the successful validation study.